ProCE Banner Activity

ACTG A5359 LATITUDE: Long-Acting CAB + RPV vs Oral ART in People Living With HIV With Adherence Challenges

Conference Coverage

In people living with HIV with adherence challenges, initial results from the phase III LATITUDE study showed fewer regimen failures with LA CAB + RPV vs standard-of-care oral ART—demonstrating superior efficacy.

Released: March 08, 2024

Expiration: March 07, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare